← Leaderboards
Marcos De Lima
University Of Texas Md Anderson Can Ctr
$1,407,443
Attributed
$2,605,680
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $609.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,605,680 · 4
By mechanism
R01$1,797,355 · 1
R21$584,389 · 1
U10$147,391 · 1
P30$76,545 · 1
Top collaborators
- Lapo Alinari3 shared
- Sumithira Vasu3 shared
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadImmuneT-LymphocyteClinical TrialsRelapse RiskSeveritiesNeoplastic CellLymphomaPreventPre-ClinicalCellular ImmunotherapyRelapseAntigensCytokineCohortFlow CytometryIncidenceFundingInnovationRefractoryMediatingChimeric Antigen Receptor T CellsCellular Indexing Of Transcriptomes And Epitopes By SequencingChronic Lymphocytic Leukemia
Grant awards (7)
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies$609,273
R01 · FY2025 · CA
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies$578,809
R01 · FY2024 · CA
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies$609,273
R01 · FY2023 · CA
Hematopoietic and Immune Cancer Biology Research Program$76,545
P30 · FY2020 · CA · contact PI
Case BMT CTN: Antibacterial Prophylaxis in Post-Engraftment Allogeneic HCT$147,391
U10 · FY2016 · HL · contact PI
A Novel Autotransplant Protocol for CML$286,967
R21 · FY2005 · CA
A Novel Autotransplant Protocol for CML$297,422
R21 · FY2004 · CA